PROGRAM OVERVIEW

Oncologists and other clinicians who treat patients with gastrointestinal (GI) cancers have generally adopted molecular profiling technologies offering insight into the molecular underpinning of colorectal, gastric, esophageal, and biliary tumors. Considering the challenges of managing these tumor types, understanding these molecular alterations is critical to incorporating newly approved and emerging targeted agents, including immunotherapies. Yet, translating these findings into clinical applications can be challenging. Determining which potential biomarkers and/or druggable mutations in GI cancers that benefit patients is instrumental in improving patient outcomes. Oncologists need greater understanding and insight into the foundational genomic discoveries that underly the use of targeted entities. Tumor Board Tuesdays is a bi-weekly, Twitter-based case discussion forum led by expert faculty exploring cases in various GI malignancies. This initiative will help to provide a bridge to extend best treatment practice that will eventually benefit patients and improve outcomes in the management of GI cancers.

FACULTY CHAIR

Michael J. Pishvaian, MD, PhD Associate Professor, Department of Oncology Director of the Gastrointestinal, Development Therapeutics, and Clinical Research Programs at the NCR Kimmel Cancer Center at Sibley Memorial Hospital Johns Hopkins University School of Medicine Washington, District of Columbia Rachna T. Shroff MD, Associate Professor of Medicine University of Arizona Cancer Center Tucson, Arizona Malvi Savani, MD Resident/Fellow- College of Medicine University of Arizona Tucson, Arizona

Release date: February 23, 2021 Expiration date: February 23, 2022 Estimated time to complete activity: 60 minutes

TARGET AUDIENCE

This program is intended for clinicians involved with, or interested in, the treatment of patients with GI malignancies.

LEARNING OBJECTIVES

Upon completion of this educational activity, participants will be able to:

Identify biomarkers that are specific to advanced or metastatic bile duct cancer and that may play a role in guiding treatment selection
Analyze treatment options for patients with advanced or metastatic bile duct cancer

DIRECTIONS TO LEARNER

There are no fees for participating and receiving CME credit for this activity. During the period of February 23, 2021 through February 23, 2022, participants must:

Read the learning objectives and faculty disclosures
Complete the pretest
Study the educational activity
Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 100%.

MEDIA

Internet

ACCREDITATION STATEMENT

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Integrity Continuing Education, Inc. and Tumor Board Tuesday. Integrity Continuing Education, Inc. is accredited by the ACCME to provide continuing medical education for physicians.

CREDIT DESIGNATION

Live Participation on February 23, 2021: Integrity Continuing Education, Inc. designates this live material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Participation from February 24, 2021 – February 23, 2022: Integrity Continuing Education, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CONTACT INFORMATION

For information about ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or info@integrityce.com.

DISCLOSURE OF CONFLICTS OF INTEREST

Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated. The following faculty/planners reported the financial relationships or relationships to products or devices they have with ineligible companies related to the content of these CME activities: Michael L. Pishvaian, MD, PhD Consulting Fees: Astra Zeneca, Foundation Medicine, Merck Ownership Interest: Perthera, Inc. Rachna T. Shroff MD, MS Consulting Fees: Merck, Seattle Genetics, Exelixis, QED, Debipharm, Agios, Clovis, Incyte Research: Pieris, Taiho, Rafael Pharmaceuticals Malvi Savani, MD does not have any conflicts of interest to disclose. The Integrity Continuing Education, Inc. planners/managers do not have any conflicts of interest to disclose.

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. does not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

PRIVACY POLICY

When you participate in an online educational activity sponsored by Integrity Continuing Education, Inc., you will be asked for your name, degree(s), affiliation(s), street address, telephone number, fax number, and…(continued)

MINIMUM SYSTEM REQUIREMENTS

Minimum Processor: Intel Pentium 4, 2.33 + GHz (or equivalent) Operating Systems: Windows XP, Windows 2000, Windows Vista, Windows 7, Windows 10, and Mac OS Plug-in: Adobe^® Flash^® Player 10

Adobe^® Flash^® Player 10 plug-in should be downloaded
Click on the “Agree and install now” button after unchecking the optional McAfee Security Scan Plus

For optimal performance, the use of Internet Explorer below 8 is not recommended. For a full listing of recommended operating systems, browsers, and system configurations, please click on the link below Click here for more information on minimum system requirements.

DISCLAIMER

The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient's medical condition.

PROVIDER STATEMENT

Provided by Integrity Continuing Education, Inc.

SUPPORTER ACKNOWLEDGEMENT

Support for this program is provided by Integrity Continuing Education, Inc.

Tumor Board Tuesday: Case of FGFR Fusion and IDH2 Mutant Cholangiocarcinoma